Objective: Brief measures of depressive symptoms and family psychiatry history may support the identification of youth who warrant further assessment, but their interpretation requires population-based measurement evidence. This study evaluated the Very Quick Inventory of Depressive Symptomatology (VQIDS) and Family In...
G. Algorta, L. Li, Y. Liu et al.· medRxiv· 0 citations
Abstract Background Treatment-resistant depression (TRD), characterized by marked symptom burden and poor daily function and quality of life (QoL), remains a major clinical challenge. Greater degrees of treatment resistance (more failed trials) are associated with lower rates of initial benefit and higher rates of rela...
A. Rush· International Journal of Neu...· 0 citations
Abstract Background Individuals with markedly treatment-resistant depression (mTRD) have substantial risk for suicide attempt and completion. Few antidepressant treatments offer benefit for suicide, and it is critical that novel treatments not increase/worsen suicidal ideation (SI) or behavior. Aims & Objectives Assess...
A. Rush, V. Hristidis, V. D. de Leon et al.· International Journal of Neu...· 0 citations
Multiple lines of current exploration are summarized including: engagement of multiple neurotransmitter systems (monoamines and others), anti-inflammatory effects, impact on brain networks/regions associated with depression, evidence of neuroplasticity in brain circuits, modulation of the autonomic nervous system, and...
Karim Al Hasanieh, C. Zorumski, H. Sackeim et al.· Current Addiction Report· 0 citations
Abstract Background In RECOVER, a 12-month, double-blind, randomized, controlled trial (RCT) comparing active versus sham adjunctive vagus nerve stimulation (VNS) in persons with markedly treatment-resistant depression (mTRD), total scores on the Quick Inventory of Depressive Symptomology–Clinician (QIDS-C) and –Self-R...
A. Rush, H. Sackeim, Y.-C. Lee et al.· International Journal of Neu...· 0 citations
Over 80% of participants who achieved meaningful benefit in symptom, function, or QoL measures after 12 months of active VNS retained these benefits at the 18- and 24-month assessments, demonstrating remarkable durability in participants expected to relapse at high rates.
C. Conway, H. Sackeim, A. Rush et al.· American Journal of Psychiat...· 2 citations
Mixed features were highly prevalent and associated with greater clinical burden, and Assessment of mixed features may provide clinically relevant information when selecting next-step pharmacologic strategies, particularly when considering a switch to bupropion sustained release.
Sidney Zisook, Lori L Davis, Trisha Suppes et al.· Journal of Psychopharmacolog...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
